Clinical trial of megakaryocyte progenitor generated from cord blood to treat thrombocytopenia after chemotherapy or radiotherapy of hematolgical maligance

Treatment of hematopoietic injury of hematolgical maligance after chemotherapy or radiotherapy

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001691

Enrollment

Unknown

Registered

2011-10-13

Start date

2011-06-14

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematolgical maligance

Interventions

1:transfusion of megakaryocyte progenitor generated

2:basal treatment

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. age: 18-70 years old; 2. male or female; 3. cin first complete remission; 4. prepare to receive two courses of the same consoldation chemotherapy; 5. predictive survival over three months; 6. PS score(ECOG) 0 or 1.

Exclusion criteria

Exclusion criteria: 1. thrombocytopenia unrelate to chemotherapy or radiotherapy of hematolgical magligance; 2. severe injury of organ function; 3. prognacy or in the period of breast-feed; 4. not assign informed consent.

Design outcomes

Primary

Measure	Time frame
recovery time of platele;	—

Contacts

Public ContactXiaojun Huang

xjhrm@medmail.com.cn+86 13701389625

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 1, 2026